|Home||Company Search||Related Articles||Forum (new!)|
|Company||GlaxoSmithKline [Company Info]|
|Track this Company (an email will be sent to you everytime a report is filed about this company)|
|10th Aug 2006||Other Issue||Glaxo pays $70m to end price row|
|GlaxoSmithKline has agreed to pay out $70m (£36.9m) to settle numerous civil claims of price-fixing in the US.
Several states, health plans and numerous consumers had launched legal action against the group claiming it had inflated the price of some drugs.
The drug maker has admitted no wrongdoing, but said it had made the move to "put the matter behind it".
Glaxo, which earned $2.42bn in the second quarter, said it had already set aside the money for the settlement.
The settlement covers claims by the states of New York, California, Nevada, Connecticut, Montana and Arizona, as well as potential claims in 34 other states and the District of Columbia.
It also resolves a lawsuit filed in Boston by individuals, health care schemes and insurers.
The lawsuits stem from claims that Glaxo used illegal schemes to inflate the price of drugs - including cancer treatments Zofran and Kytril - costing consumers and government health plans hundreds of millions of dollars.
The cases centre on the difference between set rates - or average wholesale prices - that insurance companies and government health plans, such as Medicare and Medicaid, use to reimburse physicians and pharmacies for certain drugs and the amounts the drug companies actually charge.
However, Glaxo's spokeswoman said that the practice was common in the industry.
She added that testimony showed states and health plans chose to use the set price for the drugs although it was "widely known" that this exceeded the price paid by doctors and pharmacies.
New York Attorney General Eliot Spitzer said the agreement - which settles a case he launched in 2003 - would "provide significant restitution for consumers and the Medicaid program".
|Other Reports on GlaxoSmithKline|
|29th Jan 2007||Questionable Practice||GlaxoSmithKline||GSK hid paxil suicide link|
|29th Mar 2006||Questionable Practice||GlaxoSmithKline||Glaxo agrees US Paxil settlement|
|18th Mar 2005||Other Issue||GlaxoSmithKline||Glaxo shares dip on factory probe|
|22nd Sep 2004||Questionable Practice||GlaxoSmithKline||Glaxo drops appeal in Aids drug pricing case|
|6th Sep 2004||Other Issue||GlaxoSmithKline||GSK faces anti-depressant lawsuit|
|19th May 2004||Other Issue||GlaxoSmithKline||New York sues GlaxoSmithKline|
|11th May 2004||Fraud Investigation||GlaxoSmithKline||GlaxoSmithKline faces antitrust investigation|
|22nd Jan 2004||Fraud Investigation||GlaxoSmithKline||$11.1 Million settlement|
|8th Jan 2004||Questionable Practice||GlaxoSmithKline||£1.5bn Tax Bill|
|16th Dec 2003||Questionable Practice||GlaxoSmithKline||Glaxo's CEO to scoop 5.7 mln stg a year|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||FDA tells Glaxo to pull misleading Flonase ads|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||Ordered to pull misleading adverts|
|Related Reports from the Pharamaceutical Industry|
|Merck||Other Issue||Vioxx drug ban hits Merck profits|
|Merck||Other Issue||Merck denies heart attack claim|
|Bristol-Myers Squibb||Fraud Investigation||Drugs firm settles fraud charges|
|Merck||Questionable Practice||Merck shares dive on Vioxx fears|
|Pfizer||Questionable Practice||Pfizer to use DART for online campaigns|
|© 2006 Corp-Ethics.com | Corporate Ethics|